Immunophenotypic Implications of Reverse-Circadian Glucocorticoid Treatment in Congenital Adrenal Hyperplasia

被引:0
|
作者
Nowotny, Hanna F. [1 ]
Choi, Hannah [1 ]
Ziegler, Selina [1 ]
Doll, Natalie [1 ]
Baeuerle, Ariane [1 ]
Welp, Ann-Christin [1 ]
Dubinski, Ilja [2 ]
Schiergens, Katharina [2 ]
Neumann, Uta [3 ]
Tschaidse, Lea [1 ]
Auer, Matthias K. [1 ]
Rothenfusser, Simon [4 ,5 ]
Schmidt, Heinrich [2 ]
Reisch, Nicole [1 ]
机构
[1] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, Dept Med 4, D-80336 Munich, Germany
[2] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, Dr Von Hauner Childrens Hosp, Dept Pediat, D-80336 Munich, Germany
[3] Charite Univ Med Berlin, Klin Padiatr Endokrinol & Diabetol, D-13353 Berlin, Germany
[4] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, Div Clin Pharmacol, D-80337 Munich, Germany
[5] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth Neuherberg, Einheit Klin Pharmakol EKLiP, D-85764 Oberschleissheim, Germany
关键词
circadian; glucocorticoids; immunophenotype; congenital adrenal hyperplasia; MODIFIED-RELEASE HYDROCORTISONE; REGULATORY T-CELLS; CHILDREN; IDENTIFICATION; INSUFFICIENCY; MORTALITY; THERAPY; HEALTH; ADULT; SLEEP;
D O I
10.3390/ijms26041479
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) requires lifelong glucocorticoid replacement to manage cortisol deficiency and excessive androgen production. Conventional circadian treatment (CT) tries to mimic natural cortisol rhythms, whereas reverse-circadian treatment (RC) prioritizes the suppression of adrenal androgen excess overnight through evening dosing. Limited data exist on the immunological impact of these regimens. A bi-centric study was conducted, including 41 pediatric and adolescent CAH patients. Peripheral blood samples were collected from patients on conventional treatment (n = 38) or RC (n = 16), with 11 RC patients switching to conventional treatment. Immune cell phenotypes, cytokine profiles, and natural killer (NK) cell cytotoxicity were assessed. Patients receiving RC showed lower percentages of CD4+CD25+ T cells (p = 0.0139). After the switch, patients with RC presented with a higher percentage of non-classical monocytes (p = 0.0255) and a lower percentage of Th17 cells (p = 0.0195). A lower expression of CD107 was observed with RC (p < 0.0001), as well as a higher percentage of NKp30 (p = 0.0189). Comparing patients after the switch from RC to HC, patients with RC presented with a lower NKG2D expression (p = 0.0420). Both conventional treatment and RC exhibited distinct immunological impacts, with CT showing modest advantages in normalizing immune phenotypes. These findings suggest that CT may offer immunological benefits for managing young patients with congenital adrenal hyperplasia.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Reverse circadian glucocorticoid treatment in prepubertal children with congenital adrenal hyperplasia
    Dubinski, Ilja
    Dalla-Pozza, Susanne Bechtold
    Bidlingmaier, Martin
    Reisch, Nicole
    Schmidt, Heinrich
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2021, 34 (12): : 1543 - 1548
  • [2] White matter variations in congenital adrenal hyperplasia: possible implications for glucocorticoid treatment
    Luders, Eileen
    Spencer, Debra
    Gaser, Christian
    Thankamony, Ajay
    Hughes, Ieuan A.
    Srirangalingam, Umasuthan
    Gleeson, Helena
    Kung, Karson T. F.
    Cabeen, Ryan P.
    Hines, Melissa
    Kurth, Florian
    BRAIN COMMUNICATIONS, 2024, 6 (05)
  • [3] Congenital adrenal hyperplasia and glucocorticoid monitoring
    Broeks, Ilse
    Otten, Barto
    Rouwe, Catrienus
    Bakker-van Waarde, Willie
    HORMONE RESEARCH, 2008, 70 : 143 - 143
  • [4] Lost lessons of glucocorticoid potency and the treatment of children with congenital adrenal hyperplasia
    Rivkees, Scott A.
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2008, 21 (04): : 297 - 299
  • [5] Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia
    Han, T. S.
    Stimson, R. H.
    Rees, D. A.
    Krone, N.
    Willis, D. S.
    Conway, G. S.
    Arlt, W.
    Walker, B. R.
    Ross, R. J.
    CLINICAL ENDOCRINOLOGY, 2013, 78 (02) : 197 - 203
  • [6] Glucocorticoid receptors in patients with congenital adrenal hyperplasia
    Saka, N
    Güven, M
    Bas, F
    Darendeliler, F
    Bundak, R
    Günöz, H
    Sultuybek, G
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2000, 13 (08): : 1101 - 1107
  • [7] Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms
    Bancos, Irina
    Kim, Hyunwoo
    Cheng, Henry K.
    Rodriguez-Lee, Mariam
    Coope, Helen
    Cicero, Samantha
    Goldsmith, Hannah
    Lin, Vivian H.
    Jeha, George S.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2025, 20 (01) : 33 - 49
  • [8] POSTURAL HYPOTENSION AS EVIDENCE OF INADEQUATE GLUCOCORTICOID TREATMENT IN CONGENITAL ADRENAL-HYPERPLASIA
    KIRKLAND, JL
    KIRKLAND, RT
    CLAYTON, GW
    JOURNAL OF PEDIATRICS, 1974, 85 (06): : 870 - 870
  • [9] TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
    MIGEON, CJ
    MODERN TREATMENT, 1966, 3 (06): : 1348 - +
  • [10] Pharmacogenomic markers of glucocorticoid response in congenital adrenal hyperplasia
    Barra, Cristina Botelho
    Villela, Thais Ramos
    Soares, Nedstani de Freitas
    Colosimo, Enrico Antonio
    Belisario, Andre Rolim
    Simoes e Silva, Ana Cristina
    Silva, Ivani Novato
    PLOS ONE, 2022, 17 (12):